Enanta Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 75.88. In total, the insiders bought 2 027 230 and sold 169 184 ENTA shares in the last 100 trades.

Insider Power

(Last 100 transactions)
75.88
Buy 2 027 230 Shares
Sell 169 184 Shares

Historical Insider Trades

Date Type Action Person Amount
Mar 13, 2025 Stock Option (right to buy) Buy Vance Terry 15 700
Mar 13, 2025 Stock Option (right to buy) Buy Russell Lesley 15 700
Mar 13, 2025 Stock Option (right to buy) Buy Peterson Kristine 15 700
Mar 13, 2025 Stock Option (right to buy) Buy Hata Yujiro S 15 700
Mar 13, 2025 Stock Option (right to buy) Buy Foletta Mark G 15 700
Mar 13, 2025 Stock Option (right to buy) Buy Carter Bruce L A 15 700
Feb 12, 2025 Common Stock Buy Luu Brendan 7 500
Feb 12, 2025 Common Stock Sell Luu Brendan 3 326
Feb 12, 2025 Common Stock Buy Kieffer Tara Lynn 7 500
Feb 12, 2025 Common Stock Sell Kieffer Tara Lynn 3 326
Feb 12, 2025 Common Stock Buy Rottinghaus Scott T. 9 750
Feb 12, 2025 Common Stock Sell Rottinghaus Scott T. 2 861
Feb 12, 2025 Common Stock Buy Or Yat Sun 9 750
Feb 12, 2025 Common Stock Sell Or Yat Sun 4 324
Feb 12, 2025 Common Stock Buy Mellett Paul J 7 500
Feb 12, 2025 Common Stock Sell Mellett Paul J 3 326
Feb 12, 2025 Common Stock Buy Luly Jay R. 25 500
Feb 12, 2025 Common Stock Sell Luly Jay R. 7 484
Feb 12, 2025 Common Stock Buy Luly Jay R. 45 000
Dec 06, 2024 Common Stock Sell Kieffer Tara Lynn 2 283
Dec 06, 2024 Common Stock Sell Luu Brendan 2 283
Dec 06, 2024 Common Stock Sell Rottinghaus Scott T. 866
Dec 06, 2024 Common Stock Sell Or Yat Sun 2 591
Dec 06, 2024 Common Stock Sell Mellett Paul J 2 591
Dec 06, 2024 Common Stock Sell Luly Jay R. 5 142
Click to get the best stock tips daily for free!
ABOUT ENANTA PHARMACEUTICALS
Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A pro...
GOLDEN STAR
Ticker Change Signal Date
CACC
$487.05
2.63% Jun 04
G
GTM
$9.57
2.09% Jun 02
TAC
$8.90
26.97% May 12
UAA
$5.84
8.39% May 09
HBM
$7.41
33.33% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE